| Characteristic | Novel non-opioids | Novel opioids | Non-NME non-opioids | Non-NME opioids |
|---|---|---|---|---|
| - | - | - | - | - |
| - | - | - | - | - |
| - | - | - | - | - |
| - | - | - | - | - |
The chart is not accessible to screen readers. Please switch to the table view to access the data.
Download
Region
United States
Survey time period
as of 2017
Special properties
220 ongoing clinical programs for pain indications
Supplementary notes
NDA/BLA = new drug application/biologic license application
NME = new molecular entity
Citation formats









